Cited by 51Liver Disease Diagnosis and TreatmentLiver Disease and TransplantationLiver physiology and pathology

Meta-analysis: enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases

Open access
Hinkson, Alexander, Lally, Hannah, Gibson, Hannah, Jones, Rebecca, Rowe, Ian A., Shinkins, Bethany, Parker, Richard·2023·Alimentary Pharmacology & Therapeutics

Abstract

BACKGROUND & AIMS: Patients with liver disease can be stratified for risk of liver-related ill health by degree of hepatic fibrosis. The Enhanced liver fibrosis (ELF) test was developed to quantify hepatic fibrosis non-invasively and is widely used. The objective of this review was to identify and synthesise the evidence on the diagnostic accuracy of the ELF test for staging of hepatic fibrosis. APPROACH & RESULTS: Searches of PubMed and EMBASE were conducted between October 2020 and November 2021 to identify studies reporting the diagnostic accuracy of the ELF test compared to histology in liver disease patients. QUADAS-2 was used to assess risk of bias in each study. Meta-analysis using the multiple thresholds model described by Steinhauser S, Schumacher M, Rücker G. Modelling multiple thresholds in meta-analysis of diagnostic test accuracy studies. BMC Med. Res. Methodol. 2016;16. 10.1186/s12874-016-0196-1 allowed synthesis of 2 × 2 data at different cut-offs. Sixty-three studies were included in this review. These studies included 19,285 patients with or at risk of liver disease from viral hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-related Liver Disease and other mixed chronic liver diseases. The prevalence of significant fibrosis, advanced fibrosis and cirrhosis was 47.5%, 39.2% and 4.4%, respectively. Cut-offs with maximal Youden index were generated with AUROC = 0.811 (95% CI: 0.736-0.870), 0.812 (95% CI: 0.758-0.856) and 0.810 (95% CI: 0.694-0.888) to detect significant fibrosis, advanced fibrosis or cirrhosis, respectively. Diagnostic accuracy of the ELF test varied between different liver diseases and cut-offs to detect each stage with 95% sensitivity or specificity were also generated. CONCLUSIONS: Meta-analysis revealed considerable variability in the ability of ELF to stage fibrosis across disease aetiologies. Research has mostly focused on viral hepatitis and NAFLD. There is currently a lack of data on the value of the ELF test in Alcohol-related liver disease and patients in primary care settings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.17385

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hinkson, A., Lally, H., Gibson, H., Jones, R., Rowe, I. A., Shinkins, B., & Parker, R.
Affiliations
  • University of Leeds (GB)
  • Leeds Teaching Hospitals NHS Trust (GB)
Corresponding author
Hinkson, Alexander
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2023-01-17
Volume
57
Issue
7
Pages
750-762
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W4317104619
Cited by
51
References
105
Citations by year
2026: 22 · 2025: 15 · 2024: 6 · 2023: 8
FWCI
1.98
Type
journal article
Language
en
Open access
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
enhanced liver fibrosis test, liver fibrosis, noninvasive fibrosis staging, diagnostic accuracy, chronic liver disease, viral hepatitis, non-alcoholic fatty liver disease, alcoholic liver disease, liver cirrhosis, histopathological confirmation, cut-off values
MeSH terms
Biopsy, Humans, Liver, Liver Cirrhosis, Liver Function Tests, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review